Differential effects of olanzapine and clozapine on plasma levels of adipocytokines and total ghrelin

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 58, Issue , 2015, Pages 47-50

  Lu, Mong Liang ^a   Wang, Tsu Nai ^b   Lin, Tsang Yaw ^c   Shao, Wen Chuan ^c   Chang, Sheng Huang ^c   Chou, Jen Yu ^d   Ho, Yi Feng ^e   Liao, Yin To ^e,f   Chen, Vincent Chin Hung ^e,f  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c Tsaotun Psychiatric Center Department of Health   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^f CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Adiponectin; Clozapine; Ghrelin; Leptin; Olanzapine; Schizophrenia

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CHOLESTEROL; CLOZAPINE; GHRELIN; GLUCOSE; LEPTIN; OLANZAPINE; TRIACYLGLYCEROL; BENZODIAZEPINE DERIVATIVE; GLUCOSE BLOOD LEVEL; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENERGY BALANCE; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MONOTHERAPY; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT GAIN; AGING; BLOOD; COMPARATIVE STUDY; DIET RESTRICTION; DRUG EFFECTS; METABOLISM; MIDDLE AGED;

ADIPOKINES; ADULT; AGING; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL; CLOZAPINE; FASTING; FEMALE; GHRELIN; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; TRIGLYCERIDES;

EID: 84920167933     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2014.12.001     Document Type: Article

References (40)

1. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999, 156:1686-1696.
2. Bai Y.M., Chen T.T., Yang W.S., Chi Y.C., Lin C.C., Liou Y.J., et al. Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study. Schizophr Res 2009, 111:1-8.
3. Brown S., Kim M., Mitchell C., Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry 2010, 196:116-121.
4. Casey D.E. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med 2005, 118(Suppl. 2):15S-22S.
5. Chen V.C., Wang T.N., Lu M.L., Chou J.Y., Ju P.C., Wu J.Y., et al. Weight gain and ghrelin level after olanzapine monotherapy. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:632-635.
6. Deng C., Weston-Green K., Huang X.F. The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:1-4.
7. Esen-Danaci A., Sarandol A., Taneli F., Yurtsever F., Ozlen N. Effects of second generation antipsychotics on leptin and ghrelin. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1434-1438.
8. Feng S., Melkersson K. Metabolic parameters and long-term antipsychotic treatment: a comparison between patients treated with clozapine or olanzapine. Neuro Endocrinol Lett 2012, 33:493-498.
9. Friedman J.M., Halaas J.L. Leptin and the regulation of body weight in mammals. Nature 1998, 395:763-770.
10. Gautron L., Elmquist J.K. Sixteen years and counting: an update on leptin in energy balance. J Clin Invest 2011, 121:2087-2093.
11. Herran A., Garcia-Unzueta M.T., Amado J.A., de La Maza M.T., Alvarez C., Vazquez-Barquero J.L. Effects of long-term treatment with antipsychotics on serum leptin levels. Br J Psychiatry 2001, 179:59-62.
12. Himmerich H., Fulda S., Kunzel H.E., Pfennig A., Dzaja A., Cummings D.E., et al. Ghrelin plasma levels during psychopharmacological treatment. Neuropsychobiology 2005, 52:11-16.
13. Horvath T.L., Diano S., Sotonyi P., Heiman M., Tschop M. Minireview: ghrelin and the regulation of energy balance-a hypothalamic perspective. Endocrinology 2001, 142:4163-4169.
14. Hosojima H., Togo T., Odawara T., Hasegawa K., Miura S., Kato Y., et al. Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J Psychopharmacol 2006, 20:75-79.
15. Huang M.C., Lu M.L., Tsai C.J., Chen P.Y., Chiu C.C., Jian D.L., et al. Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. Acta Psychiatr Scand 2009, 120:274-280.
16. Jalovaara K., Santaniemi M., Timonen M., Jokelainen J., Kesaniemi Y.A., Ukkola O., et al. Low serum adiponectin level as a predictor of impaired glucose regulation and type 2 diabetes mellitus in a middle-aged Finnish population. Metabolism 2008, 57:1130-1134.
17. Jin H., Meyer J.M., Mudaliar S., Jeste D.V. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr Res 2008, 100:70-85.
18. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988, 45:789-796.
19. Kluge M., Schuld A., Schacht A., Himmerich H., Dalal M.A., Wehmeier P.M., et al. Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. Psychoneuroendocrinology 2009, 34:118-128.
20. Krakowski M., Czobor P., Citrome L. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. Schizophr Res 2009, 110:95-102.
21. Leidy H.J., Gardner J.K., Frye B.R., Snook M.L., Schuchert M.K., Richard E.L., et al. Circulating ghrelin is sensitive to changes in body weight during a diet and exercise program in normal-weight young women. J Clin Endocrinol Metab 2004, 89:2659-2664.
22. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41.
23. Melkersson K.I., Dahl M.L. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology (Berl) 2003, 170:157-166.
24. Murashita M., Kusumi I., Hosoda H., Kangawa K., Koyama T. Acute administration of clozapine concurrently increases blood glucose and circulating plasma ghrelin levels in rats. Psychoneuroendocrinology 2007, 32:777-784.
25. Nasrallah H.A. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008, 13:27-35.
26. Newcomer J.W. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007, 68(Suppl. 1):20-27.
27. Palik E., Birkas K.D., Faludi G., Karadi I., Cseh K. Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics. Diabetes Res Clin Pract 2005, 68(Suppl. 1):S60-S64.
28. Reynolds G.P., Kirk S.L. Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacol Ther 2010, 125:169-179.
29. Rice D.P. The economic impact of schizophrenia. J Clin Psychiatry 1999, 60(Suppl. 1):4-6. [discussion 28-30].
30. Rummel-Kluge C., Komossa K., Schwarz S., Hunger H., Schmid F., Lobos C.A., et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010, 123:225-233.
31. Ryan M.C., Flanagan S., Kinsella U., Keeling F., Thakore J.H. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci 2004, 74:1999-2008.
32. Sentissi O., Epelbaum J., Olie J.P., Poirier M.F. Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review. Schizophr Bull 2008, 34:1189-1199.
33. Smith R.C., Rachakonda S., Dwivedi S., Davis J.M. Olanzapine and risperidone effects on appetite and ghrelin in chronic schizophrenic patients. Psychiatry Res 2012, 199:159-163.
34. Starrenburg F.C., Bogers J.P. How can antipsychotics cause diabetes mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins. Eur Psychiatry 2009, 24:164-170.
35. Theisen F.M., Gebhardt S., Bromel T., Otto B., Heldwein W., Heinzel-Gutenbrunner M., et al. A prospective study of serum ghrelin levels in patients treated with clozapine. J Neural Transm 2005, 112:1411-1416.
36. Togo T., Hasegawa K., Miura S., Hosojima H., Kojima K., Shoji M., et al. Serum ghrelin concentrations in patients receiving olanzapine or risperidone. Psychopharmacology (Berl) 2004, 172:230-232.
37. Tsai M.C., Chang C.M., Liu C.Y., Chang P.Y., Huang T.L. Association of serum levels of leptin, ghrelin, and adiponectin in schizophrenic patients and healthy controls. Int J Psychiatry Clin Pract 2011, 15:106-111.
38. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001, 7:941-946.
39. Yu Z., Sun L., Qi Q., Wu H., Lu L., Liu C., et al. Hypertriglyceridemic waist, cytokines and hyperglycaemia in Chinese. Eur J Clin Invest 2012, 42:1100-1111.
40. Zhang Q., Deng C., Huang X.F. The role of ghrelin signalling in second-generation antipsychotic-induced weight gain. Psychoneuroendocrinology 2013, 38:2423-2438.